Associated Papers
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.
Maslah N et al.
Nature Communications, 2025
40623967 (PubMed )
Supplement: 41467_2025_60884_MOESM3_ESM.xlsx › Supplementary_Data_1
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Incident Abdominal Aortic Aneurysm.
Tan Y et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
40336477 (PubMed )
Supplement: atvb-2024-322630-s01.pdf
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
Walter W et al.
Leukemia, 2024
39341969 (PubMed )
Supplement: 41375_2024_2425_MOESM1_ESM.pdf
Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to a new uncommon homozygous MPL p.Y591D mutation.
Ong J et al.
Haematologica, 2020
The modular network structure of the mutational landscape of Acute Myeloid Leukemia.
Ibáñez M et al.
Plos One, 2018
30303964 (PubMed )
Supplement: pone.0202926.s006.pdf
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F et al.
Expert Review of Hematology, 2017
Select a paper to view details